

# **Clinical trial results:**

An Open-label, Randomized, Crossover, Reader-blinded Study To Investigate the Effect of Prucalopride and Polyethylene Glycol 3350 on Colon Motility with Intraluminal Manometry in Subjects with Chronic Constipation

## **Summary**

EudraCT number	2012-002495-13
Trial protocol	BE
Global end of trial date	27 November 2013
Results information	
Result version number	v1 (current)
This version publication date	04 September 2018
First version publication date	13 March 2015

### **Trial information**

Trial identification		
Sponsor protocol code	SPD555-403	
Additional study identifiers		
ISRCTN number	-	
ClinicalTrials.gov id (NCT number)	NCT01707667	
WHO universal trial number (UTN)	-	
Notes:	•	

Sponsors	
Sponsor organisation name	Shire Movetis NV
Sponsor organisation address	Veedijk 58(104), Turnhout, Belgium, 2300
Public contact	Medical Communications, Shire-Movetis, 0032 14404390, shire-movetis.clinicaltrials@shire.com
Scientific contact	Medical Communications, Shire-Movetis, 0032 14404390, shire-movetis.clinicaltrials@shire.com

Notes:

Paediatric regulatory details	
Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage		
Analysis stage	Final	
Date of interim/final analysis	27 November 2013	
Is this the analysis of the primary completion data?	No	
Global end of trial reached?	Yes	
Global end of trial date	27 November 2013	
Was the trial ended prematurely?	No	

Notes:

### General information about the trial

Main objective of the trial:

To evaluate differences in pharmacodynamic effects of prucalopride and polyethylene glycol (PEG 3350) + electrolytes on the number of colonic high amplitude propagating contractions (HAPC) during a 12-hour intraluminal manometry in chronically constipated subjects.

Protection of trial subjects:

The subject's informed consent was a mandatory condition for taking part in the study. It was obtained in writing prior to the performance of any study-specific procedures. This study was conducted in accordance with International Conference on Harmonisation of Good Clinical Practice, the principles of the Declaration of Helsinki, as well as other applicable local ethical and legal requirements.

Background therapy: -		
Evidence for comparator: -		
Actual start date of recruitment	27 February 2013	
Long term follow-up planned	No	
Independent data monitoring committee (IDMC) involvement?	No	

Notes:

### **Population of trial subjects**

### Subjects enrolled per country

Subjects enrolled per age group

Country: Number of subjects enrolled	United States: 13
Worldwide total number of subjects	13
EEA total number of subjects	0

Notes:

In utero	0	
Preterm newborn - gestational age < 37 wk	0	
Newborns (0-27 days)	0	
Infants and toddlers (28 days-23 months)	0	
Children (2-11 years)	0	
Adolescents (12-17 years)	0	
Adults (18-64 years)	13	

From 65 to 84 years 85 years and over

## **Subject disposition**

### Recruitment

Recruitment details:

The study was conducted in 1 center (United States).

## **Pre-assignment**

Screening details:

Subjects were screened and entered a 10- to 19-day run in period, during which they recorded their bowel habits and rescue medication use in a daily diary and the existence of constipation was confirmed.

		_		_	
D.	_	-:	_	a	1
P	_		C D		

Period 1 title	Treatment Period 1
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Blinding implementation details:

To minimize bias, the study was reader-blinded: the tracings were read by an experienced gastroenterologist who received de-identified recordings that did not specify which treatment the subject had received.

#### Arms

Are arms mutually exclusive?	Yes
Arm title	Prucalopride-Polyethylene glycol (PEG)

### Arm description:

A single dose of prucalopride in the first period followed by 2 doses of PEG 3350 plus electrolytes in the second period.

Arm type	Experimental
Investigational medicinal product name	Prucalopride
Investigational medicinal product code	
Other name	Resolor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

One 2mg tablet administered with 125ml of water on Day 1

|--|

### Arm description:

Two doses of PEG 3350 plus electrolytes in the first period followed by a single dose of prucalopride in the second period.

Arm type	Experimental
Investigational medicinal product name	Polyethylene glycol (PEG) 3350
Investigational medicinal product code	
Other name	Movicol
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

Dosage and administration details:

13.8g-sachets of PEG 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water (125ml). Administered twice on Day 1 (once in the morning and once prior to lunch).

Number of subjects in period 1	Prucalopride- Polyethylene glycol (PEG)	Polyethylene glycol (PEG)-Prucalopride
Started	7	6
Completed	6	6
Not completed	1	0
Expulsion of colonic sensor catheter	1	-

Period 2	
Period 2 title	Treatment Period 2
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

### Blinding implementation details:

To minimize bias, the study was reader-blinded: the tracings were read by an experienced gastroenterologist who received de-identified recordings that did not specify which treatment the subject had received.

### **Arms**

Are arms mutually exclusive?	Yes
Arm title	Prucalopride-Polyethylene glycol (PEG)

### Arm description:

A single dose of prucalopride in the first period followed by 2 doses of PEG 3350 plus electrolytes in the second period.

Arm type	Experimental
Investigational medicinal product name	Polyethylene glycol (PEG) 3350
Investigational medicinal product code	
Other name	Movicol
Pharmaceutical forms	Powder for oral solution
Routes of administration	Oral use

### Dosage and administration details:

13.8g-sachets of PEG 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water (125ml). Administered twice on Day 1 (once in the morning and once prior to lunch).

Arm title	Polyethylene glycol (PEG)-Prucalopride
-----------	--

### Arm description:

Two doses of PEG 3350 plus electrolytes in the first period followed by a single dose of prucalopride in the second period.

Arm type	Experimental
Investigational medicinal product name	Prucalopride
Investigational medicinal product code	
Other name	Resolor
Pharmaceutical forms	Tablet
Routes of administration	Oral use

### Dosage and administration details:

One 2mg tablet administered with 125ml of water on Day 1

Number of subjects in period 2	Prucalopride- Polyethylene glycol (PEG)	Polyethylene glycol (PEG)-Prucalopride
Started	6	6
Completed	6	6

## **Baseline characteristics**

## **Reporting groups**

Reporting group title	Prucalopride-Polyethylene glycol (PEG)
REDOLLING GLOUD LINE	TPI III AIODH I I E-POIVEI II VIEHE UIVI OI (PI (1)
reperting group title	i racatopriae rolycettytette grycor (r 20)

Reporting group description:

A single dose of prucalopride in the first period followed by 2 doses of PEG 3350 plus electrolytes in the second period.

Reporting group title Polyethylene glycol (PEG)-Prucalopride

Reporting group description:

Two doses of PEG 3350 plus electrolytes in the first period followed by a single dose of prucalopride in the second period.

Reporting group values	Prucalopride- Polyethylene glycol (PEG)	Polyethylene glycol (PEG)-Prucalopride	Total
Number of subjects	7	6	13
Age categorical			
Units: Subjects			
18-64 years	7	6	13
Age continuous			
Units: years			
arithmetic mean	40.3	35.2	
standard deviation	± 11.04	± 13.18	-
Gender categorical			
Units: Subjects			
Female	7	6	13
Male	0	0	0
Region of Enrollment			
Units: Subjects			
United States	7	6	13

# **End points**

End points reporting groups	
Reporting group title	Prucalopride-Polyethylene glycol (PEG)

A single dose ofs

End point values	Prucalopride	PEG 3350	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	12	12	
Units: Number of HAPC with amplitude ≥100mmHg			
least squares mean (standard error)	8.7 (± 2.06)	2.9 (± 2.06)	

Statistical analysis title	Analysis of HPACs
Comparison groups	PEG 3350 v Prucalopride
Number of subjects included in analysis	24
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.012
Method	Linear Mixed-Effect Models Analysis
Parameter estimate	Mean difference (final values)
Point estimate	5.8
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.6
upper limit	9.9

Secondary: Area Under The Concentration Curve (AUC) of All HAPCs		
End point title	Area Under The Concentration Curve (AUC) of All HAPCs	
= 1 1 1 1 1 1 1	•	

End point description:

The AUC of all HAPCs during the first 12 hours after treatment was calculated as the sum of the AUC at all sensors of each HAPC at the  $\geq$ 100mmHg and  $\geq$ 20cm threshold.

This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.

End point type	Secondary
End point timeframe:	
Over 12 hours post-dose	

End point values	Prucalopride	PEG 3350	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	9	6	
Units: mmHg.sec			
least squares mean (standard error)	110204.1 (± 28279.91)	41152.7 (± 34432.61)	

Statistical analysis title	Analysis of AUC of All HAPCs
Comparison groups	PEG 3350 v Prucalopride
Number of subjects included in analysis	15
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.079
Method	Linear Mixed-Effect Models Analysis
Parameter estimate	Mean difference (final values)
Point estimate	69051.4
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12004.5
upper limit	150107.3

Secondary: The Mean Amplitude of HAPC		
End point title	The Mean Amplitude of HAPC	

End point description:

The mean amplitude of all HAPCs was calculated as the sum of the mean amplitude for each HAPC divided by the number of HAPCs.

This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.

End point type	Secondary
End point timeframe:	
Over 12 hours post-dose	

End point values	Prucalopride	PEG 3350	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	9	6	
Units: mmHg			
least squares mean (standard error)	199 (± 15.15)	189.8 (± 19.56)	

### Statistical analyses

Statistical analysis title	Analysis of Mean Amplitude of HAPC
Comparison groups	Prucalopride v PEG 3350
Number of subjects included in analysis	15
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.717
Method	Linear Mixed-Effect Models Analysis
Parameter estimate	Mean difference (final values)
Point estimate	9.2
Confidence interval	
level	95 %
sides	2-sided
lower limit	-45.3
upper limit	63.7

## **Secondary: Time to First HAPC**

End point title	Time to First HAPC

End point description:

The median (95% confidence interval) time to first HAPC after administration of investigational product with amplitude  $\geq$ 100mmHg and extension  $\geq$ 20cm.

This end point analyzed the Pharmacodynamic Analysis Set, which included all subjects in the Safety Analysis Set who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.

In the PEG 3350 group, the median time to first HAPC after administration of investigational product with amplitude  $\geq 100$ mmHg and extension  $\geq 20$ cm could not be calculated as only 6 subjects had HAPCs that met this threshold.

End point type	Secondary
End point timeframe:	
Over 12 hours post-dose	

End point values	Prucalopride		
Subject group type	Subject analysis set		
Number of subjects analysed	9		
Units: hours			
median (confidence interval 95%)	4.5 (1.5 to 9.3)		

### Statistical analyses

No statistical analyses for this end point

End point title Propagation Velocity of HAPC		
	End point title	Propagation Velocity of HAPC

End point description:

Propagation velocity was calculated as the extension divided by the duration for each HAPC. Mean propagation velocity is the sum of the propagation velocities divided by the number of HAPCs.

This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.

End point type	Secondary
End point timeframe:	
Over 12 hours post-dose	

End point values	Prucalopride	PEG 3350	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	9	6	
Units: cm/sec			
least squares mean (standard error)	0.467 (± 0.0803)	0.646 (± 0.1074)	

### Statistical analyses

Statistical analysis title	Analysis of Propagation Velocity of HAPC	
Comparison groups	Prucalopride v PEG 3350	
Number of subjects included in analysis	15	
Analysis specification	Pre-specified	
Analysis type	superiority	
P-value	= 0.18	
Method	Linear Mixed-Effect Models Analysis	
Parameter estimate	Mean difference (final values)	
Point estimate	-0.179	
Confidence interval		
level	95 %	
sides	2-sided	
lower limit	-0.465	
upper limit	0.107	

Secondary: Duration of HAPC	
End point title	Duration of HAPC

End point description:

The mean duration of all HAPCs was calculated as the sum of the duration of each HAPC divided by the number of HAPCs.

This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.

End point type	Secondary
End point timeframe:	
Over 12 hours post-dose	

End point values	Prucalopride	PEG 3350	
Subject group type	Subject analysis set	Subject analysis set	
Number of subjects analysed	9	6	
Units: sec			
least squares mean (standard error)	84.9 (± 8.05)	69.1 (± 10.75)	

Statistical analysis title	Analysis of Duration of HAPC	
Comparison groups	Prucalopride v PEG 3350	
Number of subjects included in analysis	15	
Analysis specification	Pre-specified	
Analysis type	superiority	
P-value	= 0.225	
Method	Linear Mixed-Effect Models Analysis	
Parameter estimate	Mean difference (final values)	
Point estimate	15.8	
Confidence interval		
level	95 %	
sides	2-sided	
lower limit	-12.6	
upper limit	44.3	

Secondary: Motility Index	
End point title	Motility Index

End point description:

Motility index (mmHg) was summarized for the following 3 time points: pre-dose, 0-5 hours post-dose, and 5-12 hours post-dose. The motility index is defined as the natural logarithm of all peak amplitudes of every contraction +1.

This end point analyzed the Pharmacodynamic Analysis Set, which consisted of all randomized subjects who had taken at least 1 dose of investigational product and who had 1 evaluable manometry assessment (minimum of 4 hours of manometry recordings from the intake of investigational product) for each treatment period.

End point type	Secondary
End point timeframe:	
Over 12 hours post-dose	

End point values	Prucalopride	PEG 3350	
Subject group type	Subject analysis set	Subject analysis set Subject analysis set	
Number of subjects analysed	9	11	
Units: mmHg			
least squares mean (standard error)			
Pre-dose	9.467 (± 0.4668)	8.312 (± 0.4403)	
0-5 hours post-dose	13.661 (± 0.3221)	13.349 (± 0.352)	
5-12 hours post-dose	14.208 (± 0.2976)	14.39 (± 0.2489)	

No statistical analyses for this end point

### **Adverse events**

### **Adverse events information**

Timeframe for reporting adverse events:

Up to 35 days

Assessment type Systematic

### **Dictionary used**

Dictionary name	MedDRA
Dictionary version	15.1

### **Reporting groups**

Reporting group title	Prucalopride

Reporting group description:

A single dose of 2mg prucalopride, administered orally as tablets with 125mL of water on Day 1.

Reporting group title	Polyethylene Glycol

Reporting group description:

13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1 (once in the morning and once prior to lunch).

Serious adverse events	Prucalopride	Polyethylene Glycol	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 13 (0.00%)	0 / 12 (0.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	

Frequency threshold for reporting non-serious adverse events:  $5\ \%$ 

Non-serious adverse events	Prucalopride	Polyethylene Glycol	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 13 (23.08%)	0 / 12 (0.00%)	
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 13 (7.69%)	0 / 12 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	2 / 13 (15.38%)	0 / 12 (0.00%)	
occurrences (all)	2	0	
Diarrhoea			

subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 12 (0.00%) 0
Nausea subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 12 (0.00%) 0
Rectal haemorrhage subjects affected / exposed occurrences (all)	1 / 13 (7.69%) 1	0 / 12 (0.00%) 0

## **More information**

# Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
26 September 2012	The general amendment included the following changes: 1-The medical monitor was changed 2-Due to concerns regarding the original lengthy fasting period between Day -2 and Day 1, dinner was added to Day -2 and Day -1, and an afternoon snack was added to Day -1 3-The original text on the packaging of the investigational product was corrected 4-Additional wording was added on the timing of colonic multiple sensor catheter placement 5-The original text on the reporting period for SAEs was changed from "must occur within one business day" to "must occur within 24 hours" 5-Minor editorial changes were performed

Notes:

# **Interruptions (globally)**

Were there any global interruptions to the trial? No

## **Limitations and caveats**

None reported